You are here

Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX®

August 19, 2019

Pfizer Inc. is voluntarily recalling RELPAX®(eletriptan hydrobromide) 40 mg tablets, lots AR5407 and CD4565, to the Patient level. Pfizer Inc. initiated this recall because these product lots may not meet Pfizer's in-house microbiological specification for the potential presence of Genus Pseudomonas and Burkholderia. For additional information, click here.

News Category:

CGD Category: